Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 7,581 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bone Clear all
Completed Not applicable Interventional Results available

Musculoskeletal Plasticity After Spinal Cord Injury

NCT02622295
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Single-session electrically induced exercise, Electrically-induced exercise training
Behavioral
Lead sponsor
Richard K Shields
Other
Eligibility
21 Years to 60 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 4 Interventional Results available

Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004

NCT03301857
View directory record Official record
Conditions
Giant Cell Tumor of Bone
Interventions
Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 21, 2026, 2:19 PM EDT
Withdrawn Not applicable Interventional

The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL

NCT00347737
View directory record Official record
Conditions
Osteoporosis
Interventions
teriparatide
Drug
Lead sponsor
Leland Graves III, MD
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 21, 2026, 2:19 PM EDT
Not listed Not applicable Interventional

Freedom Lumbar Disc in the Treatment of Lumbar Degenerative Disc Disease

NCT00775801
View directory record Official record
Conditions
Degenerative Disc Disease (DDD)
Interventions
FLD, Control
Device
Lead sponsor
AxioMed Spine Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
12
States / cities
Los Angeles, California • San Diego, California • Loveland, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)

NCT04614337
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
LUM-201, rhGH Norditropin® pen (34 µg/kg)
Drug
Lead sponsor
Lumos Pharma
Industry
Eligibility
3 Years to 12 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
27
States / cities
Sacramento, California • San Diego, California • Greenwood Village, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

NCT00104975
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
alemtuzumab, therapeutic allogeneic lymphocytes, fludarabine phosphate, melphalan, tacrolimus, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 21, 2026, 2:19 PM EDT
Recruiting No phase listed Observational

Conduit Cages and Fibergraft BG Putty

NCT06704919
View directory record Official record
Conditions
Degenerative Disc Disease, Herniated Disc
Interventions
Use of conduit cages and fibergraft BG Putty
Device
Lead sponsor
Nitin Agarwal
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 21, 2026, 2:19 PM EDT
Terminated Not applicable Interventional Results available

Vitamin D Levels in Children With IBD

NCT00621257
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
ergocalciferol, Cholecalciferol
Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 21 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 21, 2026, 2:19 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

NCT04603001
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
Interventions
LY3410738, Venetoclax, Azacitidine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 21, 2026, 2:19 PM EDT
Recruiting No phase listed Observational

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

NCT04489719
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Questionnaire Administration, Radium Ra 223 Dichloride
Procedure · Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
4
States / cities
Baltimore, Maryland • Bozeman, Montana • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 21, 2026, 2:19 PM EDT
Recruiting Not applicable Interventional

eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation

NCT07469592
View directory record Official record
Conditions
Stem Cell Transplantation, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
Interventions
eHealth Mindfulness-based Music Therapy (eMBMT), eHealth Mindfulness Meditation (eMM)
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 2:19 PM EDT
Withdrawn Not applicable Interventional

Artemis Proximal Femoral Nail for Internal Fixation of Intertrochanteric Femur Fractures

NCT05559736
View directory record Official record
Conditions
Intertrochanteric Fractures, Femoral Fracture, Femoral Neck Fractures
Interventions
Artemis Proximal Femoral Nail (PFN) implant
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 21, 2026, 2:19 PM EDT
Not listed Phase 4 Interventional

The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures

NCT01173081
View directory record Official record
Conditions
Fractures
Interventions
Teriparatide, Placebo
Drug
Lead sponsor
Ohio Orthopedic Center of Excellence
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Upper Arlington, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Results available

Subchondroplasty® Knee RCT

NCT03112200
View directory record Official record
Conditions
Bone Marrow Edema, Knee Pain Chronic, Knee Osteoarthritis, Osteoarthritis, Knee, Osteoarthritis
Interventions
Subchondroplasty with Arthroscopy, Arthroscopy Alone
Procedure
Lead sponsor
Zimmer Biomet
Industry
Eligibility
30 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
12
States / cities
Encinitas, California • Loma Linda, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

NCT02793544
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma, Acute Myelogenous Leukemia (AML), Acute Biphenotypic Leukemia (ABL), Acute Undifferentiated Leukemia (AUL)
Interventions
Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1, Infusion of non-T-cell depleted bone marrow on Day 0, Busulfan, Cyclophosphamide 50mg/kg/day IV on Days -2,-1, Cyclophosphamide 50mg/kg/day IV on Days -5,-4, Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1, Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4, Sirolimus, Mycophenolate mofetil, G-CSF, Pre-HCT Mesna on Days -6 and -5, Pre-HCT Mesna on Days -2 and -1, Pre-HCT Mesna on Days -5 and -4, Post-HCT Mesna
Drug · Radiation · Procedure
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
15 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 21, 2026, 2:19 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Effects of Long Term Cyclic Testosterone Administration on Muscle Function and Bone in Older Men

NCT01417364
View directory record Official record
Conditions
Sarcopenia
Interventions
Testosterone enanthate, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 75 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis

NCT01282164
View directory record Official record
Conditions
Adult Growth Hormone Deficiency, Hypothalamic-pituitary Disorders
Interventions
glucagon stimulation test and insulin tolerance test
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
4
States / cities
Boston, Massachusetts • Cleveland, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

NCT01204164
View directory record Official record
Conditions
AML, ALL, Blast Crisis, MDS, Multiple Myeloma
Interventions
TG02 citrate, Carfilzomib, Dexamethasone
Drug
Lead sponsor
Tragara Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
9
States / cities
Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 21, 2026, 2:19 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Ultralow Dose PET Imaging for 18F-NaF Uptake

NCT07284563
View directory record Official record
Conditions
Healthy Volunteer, Bone Alteration, Bone and Joint Cancer, Bone and Joint Infection, Arthritis
Interventions
18F-NaF
Drug
Lead sponsor
Akiva Mintz
Other
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 21, 2026, 2:19 PM EDT
Terminated Phase 1 Interventional

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

NCT04250051
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Newly Diagnosed Acute Myeloid Leukemia (AML), IDH1 Mutation Myeloid Neoplasms, Acute Myeloid Leukemia (AML)
Interventions
Cytarabine, Filgrastim, Fludarabine, Fludarabine Phosphate, Ivosidenib, Idarubicin
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes

NCT00380653
View directory record Official record
Conditions
Leukemias, Myelodysplastic Syndromes
Interventions
sapacitabine
Drug
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 21, 2026, 2:19 PM EDT
Active, not recruiting Phase 1 Interventional

AZD6738 for Patients With Progressive MDS or CMML

NCT03770429
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome
Interventions
AZD6738
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Results available

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

NCT03814005
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency, Liver Disease, Neoplasms
Interventions
Azacitidine, Pevonedistat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 21, 2026, 2:19 PM EDT
Completed No phase listed Observational

Needs Assessment for Individuals and Families Affected by Dyskeratosis Congenita (DC) and Related Telomere Biology Disorders (TBD)

NCT04959188
View directory record Official record
Conditions
Dyskeratosis Congenita, Telomere Biology Disorders
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 21, 2026, 2:19 PM EDT